Breadcrumb Home Studies Studies Search Filter Research Area AllBrain and Mental HealthCure and ImmunotherapyTherapeuticsTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 14 studies. IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis DAIDS Number TBD Research Area Tuberculosis Study Status In Development IMPAACT 2049: LEAP DAIDS Number TBA Research Area Tuberculosis Study Status In Development IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up IMPAACT 2003B/A5300B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) DAIDS Number 12041 Research Area Tuberculosis Study Status Closed to Accrual IMPAACT 2003/ACTG 5300: PHOENIx Feasibility Study DAIDS Number 11803 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection DAIDS Number 12026 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed Pagination Current page 1 Page 2 Next page Next
IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis DAIDS Number TBD Research Area Tuberculosis Study Status In Development
IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development
IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up
IMPAACT 2003B/A5300B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) DAIDS Number 12041 Research Area Tuberculosis Study Status Closed to Accrual
IMPAACT 2003/ACTG 5300: PHOENIx Feasibility Study DAIDS Number 11803 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection DAIDS Number 12026 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed
